Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Rad Laboratories (BIO)

Bio-Rad Q3 sales rise 2.8% to $649.7 million; GAAP net income $653.2 million

Mixed Impact 3 of 5 earnings Written later

Bio-Rad reported third-quarter 2024 net sales of $649.7 million, up 2.8% from a year earlier, led by Clinical Diagnostics. GAAP net income rose to $653.2 million, mainly from a gain on its Sartorius AG investment, while non-GAAP net income fell to $56.4 million and non-GAAP operating income declined to $73.3 million. The company kept its full-year non-GAAP revenue decline outlook of 2.5 to 4.0 percent and set a non-GAAP operating margin range of 12.75 to 13.25 percent that now includes a one-time acquired in-process R&D expense.

Key points

  • Net sales $649.7 million vs $632.1 million a year earlier; Clinical Diagnostics up 5.6% to $388.8 million, Life Science down 1.0% to $260.9 million
  • GAAP net income $653.2 million, or $23.34 per diluted share, vs $106.3 million, or $3.64, in Q3 2023
  • Non-GAAP net income $56.4 million, or $2.01 per diluted share, vs $68.1 million, or $2.33; non-GAAP operating income $73.3 million vs $81.6 million
  • Full-year 2024: non-GAAP revenue expected to decline about 2.5% to 4.0% on a currency-neutral basis; non-GAAP operating margin 12.75% to 13.25%

The filing

CompanyBio-Rad Laboratories (BIO)
Form8-K, current report
Filed with the SECOct 30, 2024, 4:17 PM ET
Accession number0000012208-24-000062

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.